問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Kaohsiung Municipal Gangshan Hospital (在職)

Digestive System Department

更新時間：2023-09-19

陳信成Chen, Shinn-Cherng
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳信成

List

22Cases

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

2011-03-01 - 2016-06-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    TSU-68

Participate Sites
14Sites

Terminated14Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB